We used a pair of OX40 antibodies with approximately four-fold difference in their ADCC activity, and found that treatment with ADCC-enhanced BAT6026 resulted in significantly fewer CD4+ T cells and Treg cells in mice tumor than with BAT6026-wt. This evidence concerns the gene CD4 and neoplasm.